Newsroom

AMSTERDAM--(BUSINESS WIRE)--PVP Labs, a clinical-stage biotechnology company, has been invited to present at the Pain Therapeutics Summit Europe, taking place in Amsterdam from May 7–8, 2026. The meeting will feature Chief Medical Officer Joe Stauffer, DO, MBA, FAPCR, who will present "Clinical & Regulatory Lessons from Taphalgin® (Lumekefamide)". An Important Regulatory Milestone A central highlight of the presentation is a recent and pivotal update from the U.S. Drug Enforcement Administr...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - November 29.04.2026 GNOV LN IE000OJ31JQ4 1,050,002.00 USD 37,772,673.43 35.974  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 29.04.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,390,531.15 27.810  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF- August 29.04.2026 GAUG LN IE000TGSG3Y5 550,002.00 USD 19,934,577.89 36.245  ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and liquid offerings of the Guardant Infinity™ platf...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 29.04.2026 FTEG.LN IE0009F7UB30 125,002.00 EUR 2,546,180.36 20.369  ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health closed a $77M Series C funding round led by Intrepid Growth Partners and GV, with participation from new and existing investors....

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifest...

NEW YORK--(BUSINESS WIRE)--American Express today introduced new and enhanced benefits on the American Express® Gold Card, including 5X Membership Rewards® points on prepaid hotels booked through AmexTravel.com or the Amex Travel App™, complimentary Hertz Five Star® status and an updated $120 Dining Credit — all with no change to the $325 annual membership fee. Eligible Gold Card Members can access a suite of special Amex Offers® and can enjoy an updated digital experience in the Amex mobile ap...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinr...